10:11 AM EDT, 09/16/2024 (MT Newswires) -- Nuvalent ( NUVL ) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat patients with non-small cell lung cancer showed "favorable tolerability."

The biopharmaceutical company said the studies have established preliminary clinical proof-of-concept for zidesamtinib and NVL-655 as "TRK-sparing TKIs that have the potential to move up the treatment paradigm."

Nuvalent ( NUVL ) said it expects pivotal data from both programs in 2025.

Shares of the company were up more than 13% in recent trading.

Price: 99.30, Change: +11.85, Percent Change: +13.55